

Financial Information for the 2nd Quarter of Fiscal Year Ending March 31, 2022(IFRS)

As of November 2, 2021

Mitsubishi Tanabe Pharma Corporation



Mitsubishi Tanabe Pharma

(Note about forward-looking information)

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.

Table of Contents

1	Summary of Financial Results for the 2nd Quarter of FY2021 Ending March 31, 2022 and Forecasts for FY2021		
	1. Summary of Financial Results for the 2nd Quarter of FY2021	...	2
	2. Summary of Forecasts for FY2021	...	2
2	Consolidated Financial Indicators for the 2nd Quarter of FY2021		
	1. Profit and Loss	...	3
	(1) Profit and Loss	...	3
	(2) Sales Revenue of Main Products	...	3
	2. Financial Statement	...	4
	(1) Balance Sheet	...	4
	(2) Cash Flow Statement	...	4
	(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems	...	4
	(4) Depreciation and Amortization Costs	...	4
3	Forecasts for FY2021		
	(1) Revised Consolidated Forecasts of Profit and Loss	...	5
	(2) Revised Sales Revenue Forecasts for Main Products	...	5
4	Quarterly Trend		
	(1) Profit and Loss	...	6
	(2) Sales Revenue of Main Products	...	7
5	Five-Year Financial Data		
	(1) Profit and Loss (2) Balance Sheet (3) Other Financial Data	...	8
	(4) Number of Employees	...	8
6	State of New Product Development (As of October 22, 2021)		
	(1) Central nervous system (2) Immuno-inflammation	...	9
	(3) Vaccines (4) Others	...	10
	Changes Since Previous Announcement	...	11

Summary of Financial Results for the 2nd Quarter of FY2021 Ending March 31, 2022 and Forecasts for FY2021

(Amounts less than ¥100 million are rounded)

<Regarding GILENYA Royalty>

As Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") announced on April 24, 2019 in the "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019", MTPC is currently in the arbitration proceedings with Novartis Pharma AG (hereinafter "Novartis"), and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts, which correspond to the clauses in the 1997 License Agreement of which Novartis has protested the validity, as our revenue because such payments do not satisfy one of the requirements under IFRS15, i.e., "Revenue under contract with customers". During the period of the arbitration proceedings, MTPC will continue the same accounting practice as MTPC did in fiscal year 2018. For fiscal year 2021, the forecast is prepared on the assumption that the arbitration procedure to continue. MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration. As for the amounts among the GILENYA Royalty amounts which will not be recognized as sales revenue, those will be recognized as revenue at the end of the arbitration, depending on the outcome of the arbitration.

1. Summary of Financial Results for the 2nd Quarter of FY2021

[Billion yen]

Revenue	190.9	Y-on-Y	3.6	1.9 %
Domestic	156.0	Y-on-Y	1.0	0.6 %
Overseas	35.0	Y-on-Y	2.7	8.3 %

• Domestic ethical drugs sales increased by 0.8% to ¥151.5 bn, due to increase of STELARA which was additionally approved for the treatment for ulcerative colitis in March 2020, SIMPONI for Rheumatoid arthritis (RA) treatment etc. and CANAGLU for type 2 diabetes mellitus treatment, despite NHI price revision conducted in April 2021 and expansion of generic drugs.

• Sales from overseas increased by 11.4% to ¥28.0 bn, due to increase of Radicava for Amyotrophic Lateral Sclerosis treatment and other products.

• Royalty revenue, etc. decreased by 2.6% to ¥7.6 bn.

[Billion yen]

Core Operating Profit*	2.6	Y-on-Y	(11.9)	(81.9 %)
------------------------	-----	--------	--------	----------

Core operating profit decreased due to increase of R&D expenses on COVID-19 vaccine and higher sales expenses in the relaxation of voluntary restrictions on activities under COVID-19 spread, etc. despite slight increase in sales revenue.

* With adoption of IFRS, the Company, its subsidiaries and its affiliates (collectively, "the Group") has introduced "core operating profit" as a major profit index to demonstrate its recurring profitability and positioned as an important indicator of business management, etc. "Core operating profit" is a profit excluding the income and loss recorded by non-recurring items specified by the Group (hereinafter "non-recurring items") from operating profit. The Company assumes gain or loss associated with a business transfer, restructuring loss, impairment losses on intangible assets associated with products and others as non-recurring items.

[Billion yen]

Operating Profit	1.0	Y-on-Y	62.9	-
------------------	-----	--------	------	---

Operating profit much increased due to disappearance of ¥84.5 bn impairment loss booked in FY2020 from NeuroDerm projects for Parkinson's disease.

[Billion yen]

Net Income Attributable to owners of the Company	(1.5)	Y-on-Y	49.5	-
--	-------	--------	------	---

2. Summary of Forecasts for FY2021

[Billion yen]

Revenue	398.0	Y-on-Y	20.2	5.4 %
Core Operating Profit	16.5	Y-on-Y	(4.5)	(21.6 %)
Operating Profit	19.5	Y-on-Y	78.0	-
Net Income Attributable to owners of the Company	10.5	Y-on-Y	57.4	-

Forecasts announced on May12, 2021 were revised. Refer to P5 "Forecasts for FY2021"

2 Consolidated Financial Indicators for the 2nd Quarter of FY2021

(Amounts less than ¥ 100 million are rounded)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	Q2 FY2021	Comparison to Previous Year			Comparison to Original		Notes [Y-on-Y comparison]
		Q2 FY2020	Increase (decrease)	Change %	Forecasts*1	Change %	
Revenue	190.9	187.3	3.6	1.9	398.0	48.0	Refer to "(2) Sales Revenue of Main Products"
Domestic	156.0	155.0	1.0	0.6	307.0	50.8	
Overseas	35.0	32.3	2.7	8.3	91.0	38.4	
Overseas sales ratio	18.3%	17.2%			22.9%		
Cost of sales	96.8	94.8	2.0	2.1	195.0	49.6	
Sales cost ratio	50.7%	50.6%			49.0%		
Gross profit	94.1	92.5	1.7	1.8	203.0	46.4	
SG&A expenses, etc.	91.5	77.9	13.6	17.4	186.5	49.1	
R&D expenses	45.2	33.9	11.3	33.3	90.5	49.9	Due mainly to increase in clinical trials costs of global products
Core operating profit	2.6	14.6	(11.9)	(81.9)	16.5	16.0	
Non-recurring items*2	(1.6)	(76.5)	74.9	-	3.0	-	Disappeared ¥84.5 impairment loss booked in FY2020 from NeuroDerm projects
Operating profit	1.0	(61.9)	62.9	-	19.5	5.3	
Net profit attributable to owners of the Company*2	(1.5)	(51.0)	49.5	-	10.5	-	

[Yen]

Exchange rate	Q2 FY2021 average	Q2 FY2020 average	FY2021 planned
USD	110.10	106.32	110.00

Effect of fluctuations in exchange rate for FY2021 Q2: Revenue increased by ¥0.9 bn. and core operating profit decreased by ¥3.9 bn.

(2) Sales Revenue of Main Products

[Billion yen]

	Q2 FY2021	Comparison to Previous Year			Comparison to Original	
		Q2 FY2020	Increase (decrease)	Change %	Forecasts*1	Change %
Domestic ethical drugs	151.5	150.3	1.2	0.8	297.6	50.9
Priority products	77.0	66.4	10.6	16.0	153.8	50.1
Stelara	23.1	14.0	9.2	65.8	46.4	49.9
Simponi	21.7	21.2	0.5	2.2	42.5	51.0
Tenelia	7.8	8.0	(0.2)	(2.0)	14.8	52.6
Canaglu	5.7	5.0	0.6	12.5	10.8	52.4
Canalia	4.9	5.0	(0.1)	(2.2)	9.5	51.4
Vafseo	0.3	0.3	0.0	11.9	1.1	31.7
Lexapro	7.6	7.6	0.0	0.1	14.7	51.8
Uplizna	0.3	-	0.3	-	1.2	24.6
Rupafin	3.6	3.2	0.4	11.5	9.1	39.4
Imusera	2.0	2.1	(0.1)	(5.2)	3.6	55.5
Vaccines	17.2	21.1	(4.0)	(18.7)	36.3	47.3
Influenza vaccine	5.5	6.3	(0.8)	(12.4)	13.5	41.1
Tetrabik	5.0	5.1	(0.2)	(3.8)	10.5	47.2
Mearubik	3.1	3.7	(0.6)	(16.3)	5.3	58.2
Varicella vaccine	2.2	2.5	(0.3)	(11.6)	4.3	51.7
JEBIK V	0.7	2.9	(2.2)	(75.7)	1.6	43.2
Long-listed drugs, etc.	57.3	62.7	(5.5)	(8.7)	107.5	53.3
Remicade	20.4	23.4	(3.0)	(12.8)	38.2	53.4
Overseas ethical drugs	28.0	25.1	2.9	11.4	79.2	35.3
Radicava	12.4	11.1	1.3	12.1	22.4	55.4
Royalty revenue, etc.	7.6	7.8	(0.2)	(2.6)	13.2	57.8
Royalty from INVOKANA	3.4	4.6	(1.2)	(25.2)	Undisclosed	-
Royalty from GILENYA*3	2.2	2.0	0.2	10.3	Undisclosed	-

*1: Forecasts announced on May12, 2021 were revised on Nov.2,2021. Refer to P5 "Forecasts for FY2021"

*2: Brackets indicate expense and loss

*3: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

2. Financial Statement

(1) Balance Sheet

[Billion yen]

	End of Q2 FY2021	End of FY2020	Increase (decrease)	Notes
Assets	1,039.8	1,053.3	(13.5)	
Non-current assets	379.8	378.4	1.4	
Property, plant and equipment	83.3	82.1	1.2	Obtain 7.2, depreciation (5.1) etc.
Goodwill	90.7	90.6	0.1	
Intangible assets	91.7	91.1	0.6	
Other non-current assets	114.1	114.7	(0.6)	
Current assets	659.9	674.8	(14.9)	
Inventories	78.8	81.7	(2.9)	
Trade and other receivables	122.7	116.0	6.7	
Other financial assets	329.4	330.1	(0.7)	
Cash and cash equivalents	97.5	114.2	(16.7)	Refer to "(2) Cash Flow Statement"
Other current assets	31.4	32.8	(1.3)	
Liabilities	233.5	236.4	(2.9)	
Non-current liabilities	122.9	108.6	14.3	
Other non-current liabilities	92.2	77.5	14.7	
Other	30.7	31.1	(0.4)	
Current liabilities	110.6	127.8	(17.2)	
Trade and other payables	32.6	29.5	3.1	
Other	78.0	98.3	(20.3)	
Equity	806.3	816.9	(10.6)	
Share capital	50.0	50.0	-	
Capital surplus	443.4	448.0	(4.5)	
Retained earnings	308.0	313.3	(5.3)	
Other components of equity	4.8	5.6	(0.8)	

(2) Cash Flow Statement

[Billion yen]

	Q2 FY2021	Q2 FY2020	Increase (decrease)
Cash and cash equivalents at beginning of year	114.2	83.1	31.2
Cash flows from operating activities	2.1	17.6	(15.5)
Profit before tax	1.3	(61.6)	62.9
Depreciation and amortization	7.2	7.6	(0.4)
Impairment loss	1.2	84.5	(83.3)
Loss (Gain) on sales of property, plant and equipment	-	(8.1)	8.1
Trade receivable and payable	(3.6)	(9.7)	6.1
Other	(4.0)	4.8	(8.9)
Cash flows from investing activities	(8.7)	6.5	(15.3)
Purchase (proceeds from sales) of property, plant and equipment	(8.2)	3.9	(12.1)
Purchase (proceeds from sales) of investments	2.5	64.7	(62.2)
Increase in deposits	(0.2)	(65.0)	64.8
Other	(2.8)	3.0	(5.8)
Cash flows from financing activities	(10.5)	(3.0)	(7.5)
Effect of exchange rate changes on cash and cash equivalents	0.4	(0.2)	0.6
Net increase(decrease) in cash and cash equivalents	(16.7)	21.0	(37.7)
Cash and cash equivalents at the end of period	97.5	104.0	(6.5)

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

occurring basis	Q2 FY2021	Q2 FY2020	Increase (decrease)
Investment in property, plant and equipment	7.2	9.4	(2.2)
Investment in information systems	0.9	0.6	0.2

(4) Depreciation and Amortization Costs

[Billion yen]

	Q2 FY2021	Q2 FY2020	Increase (decrease)
Property, plant and equipment	5.1	5.6	(0.5)
Intangible assets	0.7	0.6	0.1
Intangible assets with products	1.4	1.3	0.1

(1) Revised Consolidated Forecasts of Profit and Loss

[Billion yen]

	Revised on Nov.2	Comparison to Original on May 12			FY2020 Actual	Notes [Y-on-Y Comparison]
		amount	Increase (decrease)	Change %		
Revenue	398.0	407.5	(9.5)	(2.3)	377.8	Expecting delay in the supply to the Canadian authority of COVID-19 vaccine being developed by Medicago
Domestic	307.0	296.1	10.9	3.7	313.0	
Overseas	91.0	111.4	(20.4)	(18.3)	64.8	
Overseas sales ratio	22.9%	27.3%			17.1%	
Cost of sales	195.0	192.5	2.5	1.3	190.4	
Sales cost ratio	49.0%	47.2%			50.4%	
Gross profit	203.0	215.0	(12.0)	(5.6)	187.4	
SG&A expenses, etc.	186.5	189.0	(2.5)	(1.3)	166.4	
R&D expenses	90.5	85.0	5.5	6.5	72.6	
Core operating profit	16.5	26.0	(9.5)	(36.5)	21.0	Review contents and timing of expenses including R&D for reducing the impact of sales decline
Non-recurring items*1	3.0	4.0	(1.0)	(25.0)	(79.6)	
Operating profit*1	19.5	30.0	(10.5)	(35.0)	(58.5)	
Net profit attributable to owners of the Company*1	10.5	17.5	(7.0)	(40.0)	(46.9)	

Exchange rate

[Yen]

	Revised on Nov.2	Original on May 12	FY2020 average
USD	110.00	110.00	105.94

(2) Sales Revenue Forecasts for Main Products

[Billion yen]

	Revised on Nov.2	Comparison to Original on May 12			FY2020 Actual
		amount	Increase (decrease)	Change %	
Domestic ethical drugs	297.6	286.3	11.3	3.9	304.7
Priority products	153.8	146.6	7.2	4.9	137.7
Stelara	46.4	42.7	3.7	8.7	32.2
Simponi	42.5	41.2	1.3	3.2	42.3
Tenelia	14.8	14.4	0.5	3.1	15.1
Canaglu	10.8	10.1	0.7	7.1	10.3
Canalia	9.5	9.3	0.2	2.2	9.7
Vafseo	1.1	1.3	(0.2)	(18.0)	0.3
Lexapro	14.7	14.1	0.6	4.5	15.3
Uplizna	1.2	1.4	(0.1)	(8.8)	-
Rupafin	9.1	8.9	0.2	2.3	8.2
Imusera	3.6	3.3	0.4	10.6	4.1
Vaccines	36.3	37.0	(0.7)	(2.0)	42.6
Influenza vaccine	13.5	14.3	(0.8)	(5.7)	14.4
Tetrabik	10.5	10.8	(0.3)	(2.6)	10.9
Mearubik	5.3	5.7	(0.3)	(6.2)	6.1
Varicella vaccine	4.3	4.1	0.1	3.3	5.0
JEBIK V	1.6	1.3	0.4	31.2	5.2
Long-listed drugs, etc.	107.5	102.7	4.8	4.7	124.4
Remicade	38.2	36.5	1.7	4.6	45.4
Overseas ethical drugs	79.2	100.6	(21.3)	(21.2)	50.2
Radicava	22.4	19.8	2.6	13.3	22.0
Royalty revenue, etc.	13.2	12.3	0.9	7.2	15.9
Royalty from INVOKANA	Undisclosed	Undisclosed	-	-	9.1
Royalty from GILENYA*2	Undisclosed	Undisclosed	-	-	4.3

*1: Brackets indicate expense and loss

*2: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

4 Quarterly Trend

(Amounts less than ¥ 100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2020					FY2021		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Full-year Forecasts
Revenue	91.8 24.3%	95.5 25.3%	102.9 27.2%	87.6 23.2%	377.8 100.0%	95.4 24.0%	95.6 24.0%	398.0 100.0%
Domestic	75.7 24.2%	79.3 25.3%	86.7 27.7%	71.3 22.8%	313.0 100.0%	77.0 25.1%	79.0 25.7%	307.0 100.0%
Overseas	16.1 24.8%	16.2 25.1%	16.1 24.9%	16.3 25.2%	64.8 100.0%	18.4 20.2%	16.6 18.2%	91.0 100.0%
Cost of sales	45.6	49.2	52.4	43.2	190.4	47.6	49.2	195.0
Sales cost ratio	49.7%	51.6%	50.9%	49.3%	50.4%	49.9%	51.4%	49.0%
Gross profit	46.2 24.7%	46.3 24.7%	50.5 26.9%	44.4 23.7%	187.4 100.0%	47.7 23.5%	46.4 22.9%	203.0 100.0%
SG&A expenses, etc.	36.6 22.0%	41.3 24.8%	40.3 24.2%	48.1 28.9%	166.4 100.0%	41.9 22.5%	49.6 26.6%	186.5 100.0%
R&D expenses	15.3 21.1%	18.6 25.6%	16.4 22.6%	22.3 30.7%	72.6 100.0%	18.8 20.8%	26.4 29.2%	90.5 100.0%
Core operating profit*	9.6 45.5%	5.0 23.7%	10.2 48.4%	(3.7) (17.6%)	21.0 100.0%	5.8 35.3%	(3.2) (19.3%)	16.5 100.0%
Operating profit*	17.7 -	(79.6) -	7.2 -	(3.8) -	(58.5) -	5.8 29.8%	(4.8) (24.5%)	19.5 100.0%
Net profit attributable to owners of the Company*	11.5 -	(62.4) -	5.6 -	(1.6) -	(46.9) -	3.1 29.1%	(4.5) (43.1%)	10.5 100.0%

Note: The progress rates show in the lower of each cell, except for "cost of sales".

*Brackets indicate loss

(2) Sales Revenue of Main Products

[Billion yen]

	FY2020					FY2021		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Full-year Forecasts
Domestic ethical drugs	73.3 24.0%	77.0 25.3%	84.7 27.8%	69.7 22.9%	304.7 100.0%	74.5 25.1%	76.9 25.9%	297.6 100.0%
Priority products	33.4 24.3%	33.0 24.0%	37.3 27.1%	33.9 24.7%	137.7 100.0%	38.9 25.3%	38.1 24.8%	153.8 100.0%
Stelara	7.0 21.6%	7.0 21.7%	9.1 28.1%	9.2 28.6%	32.2 100.0%	11.4 24.6%	11.7 25.3%	46.4 100.0%
Simponi	10.7 25.2%	10.5 24.9%	11.5 27.3%	9.6 22.7%	42.3 100.0%	11.1 26.1%	10.6 24.9%	42.5 100.0%
Tenelia	4.1 27.2%	3.9 25.6%	3.9 25.6%	3.3 21.6%	15.1 100.0%	3.8 25.9%	4.0 26.7%	14.8 100.0%
Canaglu	2.5 24.6%	2.5 24.3%	3.0 28.6%	2.3 22.5%	10.3 100.0%	3.0 27.7%	2.7 24.7%	10.8 100.0%
Canalia	2.5 26.1%	2.5 25.4%	2.5 25.4%	2.2 23.1%	9.7 100.0%	2.5 26.0%	2.4 25.5%	9.5 100.0%
Vafseo	- -	0.3 88.1%	0.0 7.3%	0.0 4.7%	0.3 100.0%	0.1 7.5%	0.3 24.3%	1.1 100.0%
Lexapro	3.9 25.3%	3.7 24.4%	4.2 27.7%	3.5 22.6%	15.3 100.0%	3.9 26.9%	3.7 25.0%	14.7 100.0%
Uplizna	- -	- -	- -	- -	- -	0.1 10.2%	0.2 14.4%	1.2 100.0%
Rupafin	1.7 20.4%	1.6 19.0%	2.0 24.4%	3.0 36.2%	8.2 100.0%	1.9 20.5%	1.7 18.9%	9.1 100.0%
Imusera	1.1 26.8%	1.0 25.3%	1.1 27.1%	0.9 20.9%	4.1 100.0%	1.1 29.6%	0.9 25.9%	3.6 100.0%
Vaccines	7.5 17.6%	13.6 31.9%	14.8 34.8%	6.7 15.6%	42.6 100.0%	6.2 17.2%	11.0 30.2%	36.3 100.0%
Influenza vaccine	(0.0) (0.2%)	6.4 44.1%	7.5 52.0%	0.6 4.1%	14.4 100.0%	(0.0) (0.0%)	5.5 41.1%	13.5 100.0%
Tetrabik	2.7 24.5%	2.5 22.6%	3.0 27.7%	2.8 25.3%	10.9 100.0%	2.6 24.5%	2.4 22.6%	10.5 100.0%
Mearubik	1.9 30.9%	1.8 29.5%	1.4 22.2%	1.1 17.3%	6.1 100.0%	1.9 35.2%	1.2 23.0%	5.3 100.0%
Varicella vaccine	1.3 25.5%	1.2 24.8%	1.3 26.1%	1.2 23.6%	5.0 100.0%	1.1 26.2%	1.1 25.5%	4.3 100.0%
JEBIK V	1.4 27.9%	1.5 28.4%	1.4 27.5%	0.8 16.1%	5.2 100.0%	0.3 21.1%	0.4 22.0%	1.6 100.0%
Long-listed drugs, etc.	32.3 26.0%	30.4 24.5%	32.6 26.2%	29.1 23.4%	124.4 100.0%	29.4 27.4%	27.9 25.9%	107.5 100.0%
Remicade	11.9 26.2%	11.5 25.4%	12.1 26.6%	9.9 21.7%	45.4 100.0%	10.4 27.3%	10.0 26.1%	38.2 100.0%
Overseas ethical drugs	12.6 25.2%	12.5 24.9%	11.9 23.7%	13.2 26.3%	50.2 100.0%	14.4 18.2%	13.6 17.2%	79.2 100.0%
Radicava	5.6 25.4%	5.5 25.0%	4.9 22.1%	6.0 27.4%	22.0 100.0%	6.3 28.3%	6.1 27.1%	22.4 100.0%
Royalty revenue, etc.	3.8 23.6%	4.1 25.6%	4.6 29.0%	3.5 21.8%	15.9 100.0%	4.3 32.9%	3.3 24.9%	13.2 100.0%
Royalty from INVOKANA	2.0 22.5%	2.5 27.8%	2.8 31.2%	1.7 18.6%	9.1 100.0%	1.9 -	1.6 -	Undisclosed -
Royalty from GILENYA ¹²	1.1 24.5%	0.9 20.5%	1.2 26.8%	1.2 28.1%	4.3 100.0%	1.1 -	1.1 -	Undisclosed -

Note: The number below each cell shows the progress rate

*1: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

5 Five-Year Financial Data

(Amounts less than ¥100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2017	FY2018	FY2019	FY2020	Q2 FY2021	FY2021 forecasts
Revenues	433.9	424.8	379.8	377.8	190.9	398.0
Cost of sales	169.8	180.6	181.0	190.4	96.8	195.0
Gross profit	264.1	244.1	198.8	187.4	94.1	203.0
SG&A expenses, etc.	185.6	188.3	179.7	166.4	91.5	186.5
R&D expenses	79.1	86.5	79.4	72.6	45.2	90.5
Core operating profit	78.5	55.8	19.1	21.0	2.6	16.5
Operating profit	77.3	50.3	(6.1)	(58.5)	1.0	19.5
Net profit attributable to owners of the Company	58.0	37.4	0.1	(46.9)	(1.5)	10.5

(2) Balance Sheet

[Billion yen]

	End of FY2017	End of FY2018	End of FY2019	End of FY2020	End of Q2 FY2021
Assets	1,048.4	1,056.3	1,046.3	1,053.3	1,039.8
Non-current assets	462.9	467.9	452.8	378.4	379.8
Current assets	585.5	588.4	593.5	674.8	659.9
Liabilities	153.6	146.0	188.4	236.4	233.5
Non-current liabilities	55.4	54.3	90.3	108.6	122.9
Current liabilities	98.2	91.7	98.0	127.8	110.6
Equity	894.8	910.3	857.9	816.9	806.3

(3) Other Financial Data

[Billion yen]

	FY2017	FY2018	FY2019	FY2020	Q2 FY2021	FY2021 forecasts
Cash flows from operating activities	66.9	41.5	49.4	67.8	2.1	-
Cash flows from investing activities	(19.2)	(31.2)	(39.2)	(31.9)	(8.7)	-
Cash flows from financing activities	(32.5)	(25.9)	(37.9)	(7.2)	(10.5)	-
Investments in property, plant and equipment	6.2	8.6	15.5	20.0	8.1	15.7
Depreciation and Amortization Costs	11.5	11.5	10.9	15.2	7.2	13.6
Property, plant and equipment	7.6	7.1	7.0	11.1	5.1	9.8
Intangible assets including intangible assets with products	4.0	4.4	4.0	4.1	2.1	3.8
Ratio of equity attributable to owners of the Company to total assets [%]	84.2	85.0	81.4	76.9	76.9	-
ROE [%]	6.6	4.2	0.0	(5.6)	-	-
Basic earnings per share [¥]	103.35	66.64	0.26	(83.58)	-	-
Equity attributable to owners of the Company per share [¥]	1,574.26	1,600.64	1,519.22	1,443.99	1,424.53	-

(4) Number of Employees

	End of FY2017	End of FY2018	End of FY2019	End of FY2020	End of Q2 FY2021	Forecasts for end of FY2021
Consolidated	7,187	7,228	6,987	6,728	6,777	7,100
Non-consolidated	4,222	4,111	3,764	3,383	3,308	3,420

6 State of New Product Development (As of October 22, 2021)

(1) Central nervous system

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Bipolar disorder)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Asia Filed	Licensed from Horizon Therapeutics (Ireland)
	(Myasthenia gravis)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Filed (Apr. 2021)	Licensed from Neurocrine Biosciences (US)
		Asia Filed	
MT-210 (Risperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
ND0612 (Levodopa/Carbidopa)	Continuous SC pump (Parkinson's disease)	Global Phase 3	In-house
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Global Phase 3	In-house
MT-8554 (Elismetrep)	TRPM8 antagonist (Painful diabetic peripheral neuropathy)	Europe Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
MT-3921	Anti-RGMa antibody (Spinal cord injury)	Global Phase 2	Co-developed with Osaka University (Japan)

(2) Immuno-inflammation

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-5547 (Fasinumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 3	In-house
	(Systemic sclerosis)	Global Phase 2	
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (IgG4-related disease)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house

※ Asia: Excluding Japan and China

(3) Vaccines

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-2766	Plant-derived VLP vaccine (Prophylaxis of COVID-19)	Global Phase 3	Medicago product (Canada)
MT-8972	Plant-derived VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-derived VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-derived VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)
MT-2654	Adjuvanted plant-derived VLP vaccine (Prophylaxis of seasonal influenza/elderly)	Phase 1	Medicago product (Canada)

(4) Others

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Chronic kidney disease with type 2 diabetes mellitus)	Japan Filed (Aug. 2021)	In-house
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	China, Asia Phase 3	Licensed to Kyowa Kirin (Japan)
MT-2765	Renin inhibitor (Hypertension)	China Phase 3	Licensed to Shanghai Pharmaceuticals (China)
MT-8633/TR1801-ADC	Anti-c-Met antibody drug conjugate (Solid tumor)	Phase 1	In-house Collaborate with Open Innovation Partners (Japan)

※ Asia: Excluding Japan and China

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of Oct. 22, 2021	Origin / licensee
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Asia Filed	Korea Approved (Aug. 2021)	Licensed from Horizon Therapeutics (Ireland)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Asia Filed	Thailand Approved (Aug. 2021)	Licensed from Neurocrine Biosciences (US)
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	China Filed (Sep. 2019)	China Approved (Aug. 2021)	In-house
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Chronic kidney disease with type 2 diabetes mellitus)	Japan Phase 3	Japan Filed (Aug. 2021)	In-house
MT-3921	Anti-RGMa antibody (Spinal cord injury)	Phase 1	Global Phase 2	Co-developed with Osaka University (Japan)
MT-2271	Plant-derived VLP vaccine (Prophylaxis of seasonal influenza/adults)	Canada Filed (Sep. 2019)	Deleted (Discontinued)	Medicago product (Canada)
		Europe Phase 3		
	(Prophylaxis of seasonal influenza/elderly)	Europe Phase 3		

※ Asia: excluding Japan and China